33
total announcements
544210.BO · 15 min delayed
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the schedule of Analyst/ Investor Meetings to be held between August 12, 2026, and September 22, 2026, in various cities across India. The meetings are part of the company's efforts to engage with investors and analysts.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the schedule of analyst/investor meetings to be held in August and September 2026, including participation in various conferences and one-on-one meetings with investors.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the schedule of Analyst/ Investor Meetings to be held from August 12, 2026, to September 22, 2026, in various cities across India. The meetings are part of the company's efforts to engage with investors and analysts.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the schedule of participation in investor conferences by its officials, including Emkay 'Confluence 2026', Motilal Oswal 22nd Annual Global Group and Investor Conference, Elara India Dialogue 2026, Kotak Healthcare Forum 2026, and 11th Annual J.P. Morgan India Conference.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has published unaudited financial results for the quarter ended June 30, 2026, in newspapers and on its website.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has made available the audio recording of its Q1 FY27 earnings call on its website.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the date of its 45th Annual General Meeting and the record date for payment of final dividend for the financial year ended March 31, 2026.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced changes in its Board of Directors, with Mr. Berjis Desai resigning as Chairman and Non-Executive Director, and Mr. Raghu Kumar being appointed as an Additional Director. Mr. Satish Mehta will take over as Chairman of the Company. The changes are effective from the conclusion of the ensuing Annual General Meeting.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, showing a strong all-round performance with increased revenue, EBITDA, and PAT. The company has also announced key leadership changes, including the appointment of Mr. Satish Mehta as Chairman and Mr. Samit Mehta as COO, and the elevation of Gennova Biopharmaceuticals to a wholly-owned subsidiary.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with the Board of Directors approving the results at its meeting held on August 6, 2026. The company has enclosed the unaudited financial results and a limited review report by its statutory auditors, B S R & Co. LLP, with the announcement.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the outcome of its Board Meeting held on August 06, 2026. The Board has approved the unaudited financial results for the quarter ended June 30, 2026, and has also made several other key appointments and re-constituted some of its committees. Mr. Berjis Desai has retired as Chairman and Director, and Mr. Satish Mehta has been appointed as the new Chairman. Mr. Raghu Kumar has been appointed as an Additional Director, and Mr. Samit Mehta has been appointed as the Chief Operating Officer.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has completed the acquisition of 12.05% of Gennova Biopharmaceuticals Ltd's shares, making Gennova a wholly-owned subsidiary. The acquisition was completed on July 21, 2026, for an aggregate consideration of Rs. 2,318.7 Million.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the completion of the 2nd term of Independent Director Mr. P.S. Jayakumar, who will cease to be a Director and Chairman/Member of various Board Committees with effect from July 21, 2026.